GlassScriptPhysician profile
Thomas Foster
NPI 1992962856
$51,203.26
in general payments reported to CMS, 2019-2025
38 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,630 · 2020: $23K · 2021: $19K · 2022: $5,043 · 2023: $1,203 · 2024: $156 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $875 · Food and Beverage: $849 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $875.00 |
| Food and Beverage | $848.86 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24,960.00 | 2019-2021 | |
| Abbvie INC. | $23,189.34 | 2019-2025 | |
| Biogen, INC. | $345.09 | 2019-2025 | Tysabri |
| Novartis Pharmaceuticals Corporation | $317.11 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $277.88 | 2019-2021 | |
| Ucb, INC. | $214.84 | 2019-2021 | |
| Impel Pharmaceuticals INC. | $207.35 | 2022-2023 | Trudhesa |
| Amgen INC. | $165.88 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $139.32 | 2019 | |
| Arbor Pharmaceuticals, INC. | $127.27 | 2019 | |
| Emd Serono, INC. | $107.08 | 2019-2021 | |
| Lundbeck LLC | $101.09 | 2019-2025 | Vyepti |
| Horizon Therapeutics Plc | $86.81 | 2022 | |
| Lilly USA, LLC | $77.41 | 2019 | |
| Sunovion Pharmaceuticals INC. | $76.99 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $73.33 | 2019 | |
| Neurocrine Biosciences, INC. | $68.93 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $61.34 | 2019 | |
| Amneal Pharmaceuticals LLC | $57.03 | 2019 | |
| Celgene Corporation | $52.82 | 2021-2022 | |
| Genentech USA, INC. | $52.39 | 2019 | |
| Medtronic, INC. | $42.30 | 2021-2024 | Intellis Adaptivestim |
| Pfizer INC. | $40.13 | 2019-2024 | |
| Axsome Therapeutics, INC. | $38.64 | 2025 | Symbravo |
| Mdd US Operations, LLC | $36.72 | 2021 | |
| Avion Pharmaceuticals | $35.38 | 2022 | |
| Genzyme Corporation | $35.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.02 | 2022-2024 | Spravato |
| Adamas Pharmaceuticals, INC. | $27.09 | 2019 | |
| Upsher-Smith Laboratories LLC | $25.39 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.09 | 2019 | |
| Merz Pharmaceuticals, LLC | $21.99 | 2023 | Xeomin |
| Eisai INC. | $16.52 | 2019 | |
| Tanabe Pharma America, INC. | $16.17 | 2019 | |
| Averitas Pharma INC. | $13.99 | 2023 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $13.94 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.80 | 2020 | |
| Scilex Pharmaceuticals INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.